Protocol Ledger

NCT05948475 · Phase III · ACTIVE NOT RECRUITING

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Interventional Phase III clinical trial protocol NCT05948475 sponsored by TransThera Sciences (Nanjing) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-20 Enrollment: 200 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05948475
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)200 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05948475
Protocol FieldVerified Registry Value
NCT IdentifierNCT05948475
Consolidated Lead SponsorTransThera Sciences (Nanjing)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment200 participants (ESTIMATED)
Registered Start Date2023-12-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI